Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706072 | 0.82 | CDK8 (0.41) | IMPDH2KDM4EALDH1A1KDM4CMEN1 | |
| SCHEMBL27847925 | 0.81 | CDK8 (0.40) | IMPDH2KDM4EALDH1A1KDM4CMEN1 | |
| SCHEMBL29930920 | 0.74 | GPR119 (0.40) | — | |
| SCHEMBL2075524 | 0.73 | ALDH1A1 (0.38) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL7632528 | 0.71 | NPSR1 (0.43) | ALDH1A1NPSR1 | |
| SCHEMBL256355 | 0.70 | HASPIN (0.43) | KDM4EMAPTHASPINCYP3A4GSK3B | |
| Isoquinoline SCHEMBL11346369 | 0.68 | IMPDH2 (0.53) | IMPDH2KDM4EALDH1A1MEN1KMT2A | |
| Isoquinoline SCHEMBL4353462 | 0.67 | IMPDH2 (0.51) | IMPDH2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL24668531 | 0.67 | HASPIN (0.35) | HASPINROCK1PRKD3MAP4K4PIM1 | |
| SCHEMBL152013 | 0.67 | CYP19A1 (0.45) | IMPDH2KDM4EALDH1A1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109475-A1 | SHP-1 AGONISTS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023196409-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4003340-A2 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | Angion Biomedica Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220041597-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | IMPDH2 2636/4885KDM4E 3143/4885ALDH1A1 4740/4885 |
| US-20220041597-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | MCL1, HSPA9, USP10 | IMPDH2 4306/4885KDM4E 390/4885ALDH1A1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.